Publications

You can also find my articles on my Google Scholar profile.

The human and non-human primate developmental GTEx projects

Published in Nature, 2025

Large-scale developmental genomics study profiling cellular heterogeneity across human and non-human primate development.

Recommended citation: Coorens THH, Guillaumet-Adkins A, Kovner R, Linn RL, Roberts VHJ, ..., Sule A, et al. (2025). "The human and non-human primate developmental GTEx projects." Nature. 637(8046):557-564.
Download Paper

ATM phosphorylates PP2A subunit A resulting in nuclear export and spatiotemporal regulation of the DNA damage response

Published in Cellular and Molecular Life Sciences, 2022

Identification and characterization of novel ATM-PP2A-Aα signaling axis in DNA damage response.

Recommended citation: Sule A, Golding SE, Ahmad SF, Watson J, Ahmed MH, Kellogg GE, Bernas T, Koebley S, Reed JC, Povirk LF, Valerie K. (2022). "ATM phosphorylates PP2A subunit A resulting in nuclear export and spatiotemporal regulation of the DNA damage response." Cellular and Molecular Life Sciences. 79(12):603.
Download Paper

Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy

Published in Oncotarget, 2022

Novel therapeutic approach for Krebs-cycle-deficient renal cell carcinoma.

Recommended citation: Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Bindra RS. (2022). "Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy." Oncotarget. 13:1054.
Download Paper

Published in , 1900

PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer

Published in Journal of Controlled Release, 2020

Development of novel chronotherapeutic drug delivery system for brain cancer.

Recommended citation: Allen J, Wang J, Zolotarskaya OY, Sule A, Mohammad S, Arslan S, Godin B, Nan A, Valerie K. (2020). "PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer." Journal of Controlled Release. 321:36-48.
Download Paper

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Published in Science Advances, 2018

Preclinical development of brain-penetrant ATM inhibitor for glioblastoma treatment.

Recommended citation: Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, et al. (2018). "The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models." Science Advances. 4(6):eaat1719.
Download Paper

Published in , 1900

Radiosensitizing Glioma by Targeting ATM with Small Molecule Inhibitors

Published in Strategies to Enhance the Therapeutic Ratio of Radiation as a Cancer Treatment, 2016

Book chapter on ATM inhibition strategies for glioma radiosensitization.

Recommended citation: Sule A, Valerie K. (2016). "Radiosensitizing Glioma by Targeting ATM with Small Molecule Inhibitors." In: Strategies to Enhance the Therapeutic Ratio of Radiation as a Cancer Treatment.

Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining

Published in Oncotarget, 2015

Characterization of BRCA1 SQ-cluster role in DNA repair pathway selection.

Recommended citation: Beckta JM, Dever SM, Gnawali N, Khalil A, Sule A, Golding SE, Rosenberg E, Wheelhouse RT, Yao Z, Povirk LF, Valerie K. (2015). "Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining." Oncotarget. 6(29):27674.
Download Paper